Lymphangioleiomyomatosis

IRVINE, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer with responsibility for leading the company’s clinical development programs. “We are pleased to welcome Dr. Katz to the Eledon team,” said David-Alexandre C. Gros, M.D., Eledon Chief Executive Officer. “Dr. Katz brings a wealth of knowledge in the surgical transplantation field together with extensive experience designing and overseeing clinical trials for immunosuppressive treatments. We look forward to his leadership and contributions as we continue to advance tegoprubart for the prevention of rejection in patients undergoing transplantation procedures.” Dr. Katz is an experienced transplant surgeon with significant clinical development experience. Most recently, he was Chief Medical Officer at eGenesis where he helped lead the clinical development of eGenesis’ xenotransplantation programs. Prior to eGenesis, Dr. Katz was Vice President of Clinical Development first at Viela Bio and then at Horizon Therapeutics following its acquisition of Vielo Bio. At Horizon and Viela Bio, Dr. Katz led the clinical development of inebilizumab in multiple autoimmune indications and oversaw the regulatory submission and approval of UPLIZNA®(inebilizumab) to treat neuromyelitis optica spectrum disorder in adults. Prior to Viela Bio, Dr. Katz served as Senior Director of Clinical Development at MedImmune Inc. where he oversaw the clinical development of three different biologics. Prior to MedImmune, Dr. Katz served as Senior Director of Transplantation with the Medicine Development Group at Pfizer. At Pfizer, he oversaw multiple research programs with rapamycin, an anti-rejection drug, and was instrumental in the regulatory submission and FDA approval of rapamycin as a treatment for lymphangioleiomyomatosis (LAM), a rare and fatal lung disease. Before joining industry, Dr. Katz spent two decades as a transplant surgeon. He was director of the abdominal transplantation division at Integris Baptist Medical Center in Oklahoma City, and an associate professor of surgery and the director of the liver transplantation division at the University of Massachusetts Medical Center, Worcester, MA. Dr. Katz spearheaded liver transplantation advances at these institutions and was actively involved with policy making in organ donation and allocation. Dr. Katz earned his M.D. at Hadassah Hebrew University Medical School in Jerusalem. “With tegoprubart, Eledon is well positioned to meet the critical need for innovative transplantation immunosuppressant therapies,” said Dr. Katz. “I’m excited to join Eledon as the company continues to realize its vision to significantly improve the functional life of transplanted organs and address the side effects of current immunosuppressive treatments.” About Eledon Pharmaceuticals and tegoprubart Eledon Pharmaceuticals is a clinical stage biotechnology company with immunology expertise that is developing therapies to protect and prevent rejection of transplanted organs, as well as to treat amyotrophic lateral sclerosis (ALS). The Company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, California. For more information, please visit the company’s website at www.eledon.com. Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter Investor Contact: Stephen JasperGilmartin Group(858) 525 2047stephen@gilmartinir.com Media Contact: Jenna UrbanBerry & Company Public Relations(212) 253 8881jurban@berrypr.com Source: Eledon Pharmaceuticals

A new study uses single cell analysis of gene expression combined with spatial transcriptomics to reveal previous unrecognized immune cell types and interactions within adipose tissue. Fat tissue, for as much as it's been vilified, is an incredibly complex and essential bodily organ involved in energy storage and hormone production, among other functions. Yet, modern lifestyles have led to a worldwide epidemic of obesity, and a corresponding increase in related conditions like type 2 diabetes and cardiovascular disease. Researchers are attempting to uncover the basics of how fat tissue is structured and, specifically, inflammation associated with obesity, in the hopes of unlocking the connection between the accumulation of fat and poor health outcomes. A new study from Lindsey Muir, Ph.D., Ph.D.-candidate Cooper Stansbury, and their colleagues uses single cell analysis of gene expression combined with spatial transcriptomics to reveal previous unrecognized immune cell types and interactions within adipose tissue. Spatial transcriptomics is a newer technology that captures all gene expression in small spots across an entire thin section of tissue. Studying fat is easier said than done. In tissues that are organized into defined layers for example the spinal cord or the brain "it's easier to do sanity checks with your data and identify this or that layer as a particular cell type and know that it should be expressing genes X, Y, and Z," said Muir, a research assistant professor in the Department of Computational Medicine and Bioinformatics. "With adipose, it's a lot more challenging because the cell types are distributed evenly throughout the tissue, without defined cell layers." In obesity, fat cells, or adipocytes, expand and can reach a limit that ultimately causes cell death and leads to inflammation. To better understand the types of immune cells within adipose tissue and where they are in relation to each other in obesity, the team fed mice a high fat diet over the course of 14 weeks, collected fat tissue, and then used single cell and spatial analyses to produce a read out of all the mRNAs present in the sample. Using a computational process known as clustering in the single cell data, they were able to group cells whose genetic makeup more closely resembled each other than other groups or the overall sample. They discovered something surprising about the samples' population of macrophages, an immune cell whose job it is to clean up dead cells and debris. "We knew going in that macrophages would likely have multiple subtypes… what surprised us were the number that came out that were highly different from each other and coming up at different times and becoming more dominant over time." They identified five types, which they named Mac1, 2, 3, 4, and 5. Mac1 were resident to the tissue in both lean mice on a normal diet and obese mice. Mac2 and Mac3, which were identified by their pro-inflammatory genes, peaked after 8 weeks of the high-fat diet. However, as the high-fat diet progressed to 14 weeks, Mac4 and Mac5 cells, which had low pro-inflammatory gene expression, predominated, while pro-inflammatory Mac2 and Mac3 cells decreased. "The thinking in the field has been that the type of macrophages that accumulate in obesity are promoting an inflammatory state. Based on these data there's a lot more to the story," said Muir. Her hypothesis is that Mac4 and Mac5 are the lipid associated macrophages (LAMs) described in her own prior work and by other researchers and may be a sign of the body attempting to quell a damaging level of inflammation from pro-inflammatory macrophages and dying adipocytes. Next, painstakingly careful sectioning of fresh frozen fat tissue enabled analysis by spatial transcriptomics. Each analysis spot in the spatial method has a unique barcode that attaches to the mRNA in the tissue on top of that spot, so gene expression can later be mapped to specific locations in the tissue using the barcodes as coordinates. In this method, the sections are also imaged just prior to collection of mRNA. The study examined these images looking for tell-tale markers called crown-like structures -- structures that are associated with insulin resistance. "Once crown-like structures appear, it takes them a long time to go away and their appearance indicates tissue dysfunction," noted Muir. "Using image processing, we identified based on the density of these regions what was likely to be a crown-like structure and then went in to verify that we could see them visually," said Muir. These structures had gene expression indicating the presence of Mac4 and Mac5 LAMs. With more insight into the cellular makeup and spatial organization of fat tissue in the context of obesity, the next step, Muir said, is to examine the signaling processes and proteins associated with the development of LAMs and metabolic disorders.

DUBLIN, Aug. 14, 2023 /PRNewswire/ -- The "PEComa - Market Insights, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The global PEComa market has shown significant growth, with the United States leading the market in terms of size. In 2022, the market size in the US reached approximately USD 20 million, and it is projected to continue growing by 2032. The incidence of PEComa cases is also on the rise, with around 250 new cases reported in the US in 2022, and this number is expected to increase in the coming years. Aadi Bioscience's FYARRO is currently the only approved therapy for PEComa. It received a product-specific, permanent J-code for intravenous use in the treatment of adult patients with locally advanced unresectable or metastatic malignant PEComa. The drug targets perivascular epithelioid cells, which are responsible for the abnormal growth and stiffness seen in PEComa patients. Despite its promising potential, the high cost of FYARRO may present a challenge for its market success. The PEComa market is segmented into various specific tumor types, each with unique features and likely to form in specific body parts. These include Angiomyolipomas, Clear cell sugar tumors, Lymphangioleiomyomatosis, and others. However, currently, there are no emerging drugs in the pipeline targeting PEComa. The dynamics of the market may change in the future due to improved awareness and quicker diagnosis of the disease. The report provides comprehensive insights into the PEComa market, including historical and forecasted epidemiology, market trends, and treatment practices in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. It covers current treatment practices, emerging drugs, market share of individual therapies, and the projected market size of PEComa from 2019 to 2032 in the 7MM. In addition, the report includes detailed analysis of PEComa marketed drugs and late-stage pipeline drugs, clinical trial details, pharmacological action, approvals, and patents. Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) have been consulted to validate research findings and provide insights into current market trends and unmet needs. As the market for PEComa is expected to grow in the coming years, understanding the dynamics and opportunities in this field is essential for stakeholders in the healthcare industry. Market access and reimbursement information are also provided in the report, offering insights into the accessibility and affordability of treatments for PEComa patients. Overall, the report aims to provide a comprehensive outlook on the PEComa market, helping healthcare professionals and industry stakeholders make informed decisions and identify potential novel treatments for this rare and challenging disease. Key Topics Covered 1. Key Insights 2. Report Introduction 3. Executive Summary 4. Key Events 5. Epidemiology and Market Forecast Methodology 6. PEComa Market Overview at a Glance in the 7MM 7. Disease Background and Overview 8. Treatment 9. Guidelines 10. Epidemiology and Patient Population 11. Patient Journey 12. Key Endpoints in PEComa 13. Marketed Drugs 14. PEComa: 7MM Analysis 15. Unmet Needs 16. SWOT Analysis 17. KOL Views 18. Market Access and Reimbursement 19. Appendix For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo : SOURCE Research and Markets